License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness
Dublin, Ireland, and Tampere, Finland, 17 January 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell-based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.
StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for unmet medical needs in corneal blindness. Led by a team of expert scientists in the field of stem cells and tissue engineering for eye applications, StemSight originated as a spin-out from pluripotent stem cell pioneer Prof Heli Skottman’s laboratory at Tampere University. StemSight is at the forefront of innovative research in regenerative medicine of the cornea.
Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight. By harnessing the remarkable capabilities of CRISPR/Cas9 we will be able to address major challenges of the current allogeneic cell therapies, ultimately bringing us closer to life-changing therapies for patients with currently incurable blindness.”
Eric Rhodes, CEO of ERS Genomics, commented: “We are pleased to add StemSight to our family of licensees. This collaboration underscores the growing prominence of Finland, and the Nordics, in the global biotechnology and life science sector. StemSight’s use of CRISPR/Cas9 technology to develop regenerative therapies that will change the lives of patients suffering from limbal stem cell deficiency is truly pioneering.”
You may also like…
Powell Gilbert grows London team with four Associate hires
London - European IP law firm Powell Gilbert has today announced the expansion of its market-leading team of IP...
FisherBroyles strengthens IP group with James Vaughan and Andrew Claerbout as partners
ATLANTA—(September 15, 2025)—FisherBroyles, LLP, the world’s first and one of the largest distributed law firms, has...
Public funding specialist joins Ward Hadaway as partner
UK Top 100 law firm Ward Hadaway has appointed one of the UK’s leading public funding lawyers, Alexander Rose, as...
Contact us share your movers & shakers news